Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern

被引:80
作者
Nugiel, DA [1 ]
Vidwans, A [1 ]
Etzkorn, AM [1 ]
Rossi, KA [1 ]
Benfield, PA [1 ]
Burton, CR [1 ]
Cox, S [1 ]
Doleniak, D [1 ]
Seitz, SP [1 ]
机构
[1] Bristol Myers Squibb Co, Wilmington, DE 19880 USA
关键词
D O I
10.1021/jm020171+
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We disclose a novel series of indenopyrazole-based cyclin-dependent kinase (CDK) inhibitors. Kinetic experiments confirmed our initial molecular modeling studies that the compounds are competitive with respect to adenosine 5'-triphosphate (ATP) and bind in the kinase ATP pocket. A unique combination of active pharmacophores led us to a series of semicarbazide-based. inhibitors that are highly potent against CDK2 and CDK4 while maintaining selectivity against other relevant serine/threonine kinases. These compounds were active against a transformed human colon cancer cell line (HCT116) while maintaining an acceptable margin of activity against a normal fibroblast cell line. The compounds were found to be highly protein bound in our cell-based assay with the exception of 11k, which maintained a reasonable level of activity in the presence of human plasma proteins.
引用
收藏
页码:5224 / 5232
页数:9
相关论文
共 35 条
[1]  
Akinaga S, 2000, ANTI-CANCER DRUG DES, V15, P43
[2]   Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles [J].
Arris, CE ;
Boyle, FT ;
Calvert, AH ;
Curtin, NJ ;
Endicott, JA ;
Garman, EF ;
Gibson, AE ;
Golding, BT ;
Grant, S ;
Griffin, RJ ;
Jewsbury, P ;
Johnson, LN ;
Lawrie, AM ;
Newell, DR ;
Noble, MEM ;
Sausville, EA ;
Schultz, R ;
Yu, W .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) :2797-2804
[3]   Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases [J].
Barvian, M ;
Boschelli, DH ;
Cossrow, J ;
Dobrusin, E ;
Fattaey, A ;
Fritsch, A ;
Fry, D ;
Harvey, P ;
Keller, P ;
Garrett, M ;
La, F ;
Leopold, W ;
McNamara, D ;
Quin, M ;
Trumpp-Kallmeyer, S ;
Toogood, P ;
Wu, ZP ;
Zhang, EL .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (24) :4606-4616
[4]  
Carlson BA, 1996, CANCER RES, V56, P2973
[5]   Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase [J].
deAzevedo, WF ;
MuellerDieckmann, HJ ;
SchulzeGahmen, U ;
Worland, PJ ;
Sausville, E ;
Kim, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) :2735-2740
[6]   CRYSTAL-STRUCTURE OF CYCLIN-DEPENDENT KINASE-2 [J].
DEBONDT, HL ;
ROSENBLATT, J ;
JANCARIK, J ;
JONES, HD ;
MORGAN, DO ;
KIM, SH .
NATURE, 1993, 363 (6430) :595-602
[7]   Cell cycle control and cancer [J].
Draetta, G ;
Pagano, M .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31, 1996, 31 :241-248
[8]   Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717 [J].
Dreyer, MK ;
Borcherding, DR ;
Dumont, JA ;
Peet, NP ;
Tsay, JT ;
Wright, PS ;
Bitonti, AJ ;
Shen, J ;
Kim, SH .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (04) :524-530
[9]   3D-QSAR CoMFA on cyclin-dependent kinase inhibitors [J].
Ducrot, P ;
Legraverend, M ;
Grierson, DS .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (22) :4098-4108
[10]  
Fischer P M, 2001, Curr Opin Drug Discov Devel, V4, P623